Startseite Mild phenotype in two siblings with a missense GHR variant
Artikel
Lizenziert
Nicht lizenziert Erfordert eine Authentifizierung

Mild phenotype in two siblings with a missense GHR variant

  • Behiye Sarıkaya Özdemir ORCID logo EMAIL logo , Semra Çetinkaya ORCID logo , Naz Güleray Lafcı ORCID logo , Merve Şakar ORCID logo , Gülin Karacan Küçükali ORCID logo , Selin Elmaoğullari ORCID logo und Şenay Savaş Erdeve ORCID logo
Veröffentlicht/Copyright: 1. Juli 2021

Abstract

Objectives

 Laron syndrome (LS) is a disease caused by growth hormone receptor (GHR) defects. It is characterized by severe postnatal growth retardation and distinctive facial features.

Case presentation

In this case report, we describe the clinical and biochemical characteristics of two siblings with LS, a sister and a brother, and identify a homozygous c.344A> C (p.Asn115Thr) variant in GHR. The sister was 11 years 9 months old with a height of 127.5 cm (-3.86 SDS), and the brother was 14 years 10 months old with a height of 139 cm (-4.27 SDS). Their phenotype did not have features suggesting classical LS.

Conclusion

In the current literature, there are three cases with the same missense variant. Our cases differ from them in clinical (higher height SDS, mild dysmorphism including a broad forehead, malar hypoplasia, prominent columella and chin, thick lips) and biochemical characteristics. Here, we present the variable expressivity in the two siblings.


Corresponding author: Behiye Sarıkaya Özdemir, MD, Fellowship of Pediatric Endocrinology, Pediatric Endocrinology Department, Dr. Sami Ulus Obstetrics and Gynecology, Children’s Health and Disease Training and Research Hospital, University of Health Sciences Turkey, Dr.Sami Ulus Çocuk Hast.EAH. Babür Cad. No:44 (06080) Altındağ, Ankara, Turkey, Phone: +90 312 3056000, Mobile: +90 536 4180283, E-mail:

  1. Research funding: None declared.

  2. Author contributions: All authors have accepted responsibility for the entire content of this manuscript and approved its submission.

  3. Competing interests: Authors state no conflict of interest.

  4. Informed consent: Informed consent was obtained from all individuals included in this study.

  5. Ethical approval: Ethics committee approval is not required for this case report.

References

1. Kurtoğlu, S, Hatipoglu, N. Growth hormone insensitivity: diagnostic and therapeutic approaches. J Endocrinol Invest 2016;39:19–28.10.1007/s40618-015-0327-2Suche in Google Scholar PubMed

2. Lin, S, Li, C, Li, C, Zhang, X. Growth hormone receptor mutations related to individual dwarfism. Int J Mol Sci 2018;19:1433. https://doi.org/10.3390/ijms19051433.Suche in Google Scholar PubMed PubMed Central

3. David, A, Hwa, V, Metherell, LA, Netchine, I, Camacho-Hübner, C, Clark, AJ, et al.. Evidence for a continuum of genetic, phenotypic, and biochemical abnormalities in children with growth hormone insensitivity. Endocr Rev 2011;32:472–97. https://doi.org/10.1210/er.2010-0023.Suche in Google Scholar PubMed

4. Woods, KA, Savage, MO. Laron syndrome: typical and atypical forms. Bailliere Clin Endocrinol Metabol 1996;10:371–87. https://doi.org/10.1016/s0950-351x(96)80500-3.Suche in Google Scholar PubMed

5. Savage, MO, Blum, WF, Ranke, MB, Postel-Vinay, MC, Cotterill, AM, Hall, K, et al.. Clinical features and endocrine status in patients with growth hormone insensitivity (Laron syndrome). J Clin Endocrinol Metab 1993;77:1465–71. https://doi.org/10.1210/jcem.77.6.7505286.Suche in Google Scholar PubMed

6. Phanse-Gupte, SR, Khadilkar, VV, Khadilkar, AV. Clinical features and endocrine profile of Laron syndrome in Indian children. Indian J Endocrinol Metab 2014;18:863–7. https://doi.org/10.4103/2230-8210.140236.Suche in Google Scholar PubMed PubMed Central

7. Harding, PA, Wang, XZ, Kelder, B, Souza, S, Okada, S, Kopchick, JJ. In vitro mutagenesis of growth hormone receptor Asn-linked glycosylation sites. Mol Cell Endocrinol 1994;106:171–80. https://doi.org/10.1016/0303-7207(94)90200-3.Suche in Google Scholar PubMed

8. Savage, MO, Burren, CP, Rosenfeld, RG. The continuum of growth hormone-IGF-I axis defects causing short stature: diagnostic and therapeutic challenges. Clin Endocrinol 2010;72:721–8. https://doi.org/10.1111/j.1365-2265.2009.03775.x.Suche in Google Scholar PubMed

9. Shapiro, L, Chatterjee, S, Ramadan, DG, Davies, KM, Savage, MO, Metherell, LA, et al.. Whole-exome sequencing gives additional benefits compared to candidate gene sequencing in the molecular diagnosis of children with growth hormone or IGF-1 insensitivity. Eur J Endocrinol 2017;177:485–501. https://doi.org/10.1530/eje-17-0453.Suche in Google Scholar PubMed

10. Al-Ashwal, AA, Al-Sagheir, A, Ramzan, K, Al-Owain, M, Allam, R, Qari, A, et al.. Clinical, endocrine, and molecular genetic analysis of a large cohort of Saudi Arabian patients with Laron syndrome. Horm Res Paediatr 2017;88:119–26. https://doi.org/10.1159/000475991.Suche in Google Scholar PubMed

Received: 2021-01-20
Accepted: 2021-04-26
Published Online: 2021-07-01
Published in Print: 2021-10-26

© 2021 Walter de Gruyter GmbH, Berlin/Boston

Artikel in diesem Heft

  1. Frontmatter
  2. Review Article
  3. Stretched penile length at birth: a systematic review
  4. Original Articles
  5. Global epidemiology of mucopolysaccharidosis type III (Sanfilippo syndrome): an updated systematic review and meta-analysis
  6. Cardiometabolic risk factors in children and adolescents from southern Brazil: comparison to international reference values
  7. Association of antimullerian hormone with the size of the appendix testis, the androgen and estrogen receptors and their expression in the appendix testis, in congenital cryptorchidism
  8. The utility of serum inhibin B, anti-Müllerian hormone and insulin growth factor-1 in predicting a positive response to GnRH analogs for diagnosing central precocious puberty in girls
  9. Growth response to growth hormone (GH) treatment in children with GH deficiency (GHD) and those with idiopathic short stature (ISS) based on their pretreatment insulin-like growth factor 1 (IGFI) levels and at diagnosis and IGFI increment on treatment
  10. Association of muscle mass and fat mass on low-density-lipoprotein cholesterol and triglyceride plasma concentration in children and adolescents
  11. The effect of sickle cell anemia on the linear growth of Nigerian children
  12. Size-adjustment techniques of lumbar spine dual energy X-ray absorptiometry measurements in assessing bone mineralization in children on maintenance hemodialysis
  13. Changes in the presentation of newly diagnosed type 1 diabetes in children during the COVID-19 pandemic in a tertiary center in Southern Turkey
  14. Partial remission in children and adolescents with type 1 diabetes: an analysis based on the insulin dose-adjusted hemoglobin A1c
  15. Short Communication
  16. Anti-SARS-CoV-2 antibodies in new-onset type 1 diabetes in children during pandemic in Belgium
  17. Case Reports
  18. An intronic variant disrupts mRNA splicing and causes FGFR3-related skeletal dysplasia
  19. Auto-destruction of the thyroid gland and coexisting glutamic acid decarboxylase mediated neurological disease in an adolescent: an unusual presentation of autoimmunity
  20. Glycogen storage disease type XII; an ultra rare cause of hemolytic anemia and rhabdomyolysis: one new case report
  21. The clinical variations and diagnostic challenges of deoxyguanosine kinase deficiency: a descriptive case series
  22. Mild phenotype in two siblings with a missense GHR variant
Heruntergeladen am 5.9.2025 von https://www.degruyterbrill.com/document/doi/10.1515/jpem-2021-0044/html
Button zum nach oben scrollen